Positions

Professor & Executive Vice Chair
Menninger Dept of Psychiatry
Baylor College of Medicine
Houston, Texas, United States
Chief of Psychiatry
Harris Health System & Ben Taub Hospital
Chief/Division of Community Psychiatry
Menninger Dept of Psychiatry
Baylor College of Medicine
United States
Director
Mood Disorder Research Program at Harris Health & Ben Taub Hospital
Professor
Community and Family Medicine
Baylor College of Medicine
Director
Community Behavioral Health Program, Harris Health System
United States
Executive Director
Psychotherapy Services, Ben Taub Hospital
Faculty Senator
Baylor College of Medicine
Houston, Texas, United States

Education

Residency at Delaware State Hospital
MBBS from Dow Medical College, University of Karachi

Certifications

American Board of Psychiatry and Neurology, Inc
Fellow
American Psychiatric Association

Professional Statement

Dr. Shah is the Executive Vice Chair and Professor in the Menninger Department of Psychiatry and Behavioral Sciences, and the Department of Community and Family Medicine, Baylor College of Medicine. In September 2016, Dr. Shah was appointed as the Inaugural Vice Chair for Community Psychiatry, which has now become the Division of Community Psychiatry under his leadership as its Chief. He is also Chief of Psychiatry for Ben Taub Hospital/Harris Health System and the Director of Community Behavioral Health Program for Harris Health System. His service is the largest outpatient Mental Health provider in Harris County, with over 100,000 visits a year. He is also the Director of Mood Disorder Research Program at Ben Taub and the Executive Director of Psychotherapy Services for Ben Taub Hospital. Dr. Shah has done numerous media presentations to National and International Radio/TV/Newspapers on topics like Ketamine and Depression, Election stress, mass shootings, stress management, work related stress, ADHD, road rage, seasonal affective disorder and Phobias and has widely presented both nationally and internationally. He has received two Fulbright and Jaworski Awards, one for Teaching and Evaluation in 2012 and second for Educational Leadership in 2014. He also received Rising Star Clinician Award from Baylor in 2014. His current research is in the field of treatment resistant depression, and ketamine.

He won the Faculty of the Year Award in 2013 from Baylor¹s Psychiatric Residency Program, and in 2014 from Baylor¹s Psychology Internship Program, and also was named by Houstonia magazine in their Top Doctors list for Houston in 2013, 2014, 2015 and 2017, and Top Doctors of Houston Award by Castle Connolly in 2017. He was appointed as Board Director for Mental Health America (MHA) in June 2017.

Selected Publications

  • Shah A, Mathew S. "An Update on New Medications for the Treatment of Major Depressive Disorder." New Directions in Psychiatry. 2015;34(3):159-170.
  • Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, Iqbal S, Pillemer S, Foulkes A, Shah AA, Charney DS, Mathew SJ.. "Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial." Am J Psychiatry. 2013 October(170):1134-1142.
  • Shah AA, Awais Aftab, Coverdale J. "Review article, "QTc Prolongation with Antipsychotics: Is Routine EKG Monitoring Recommended?"." J Psychiatric Practice.
  • Mathew SJ, Shah A, Lapidus K, Clark C, Jarun N, Ostermeyer B, Murrough JW. Ketamine for Treatment-Resistant Unipolar Depression CNS Drugs: 1 March 2012 - Volume 26(3), pp 189-204. "Ketamine for Treatment-Resistant Unipolar Depression." CNS Drugs. 2012 March 1;26(3):189-204.
  • Shah A. "Update on DSM V." Pakistan Journal of Medical Students. 2012 February 22;2(2)
  • Singh H, Shah AA, Gupta V, Coverdale J, Harris T.. "Efficaciousness of Mental Health Outreach in Religious Settings." Am J Psychiatric Rehabilitation. 2012 August;15:290–298.
  • Owusu Y, Kunik M, Coverdale J, Shah AA, Primm A, Harris T.. "Lessons Learned: A Homeless Intervention By a Medical Student Academic Psychiatry." 2012 May 1:36(3):.. 2012 May 1;36(3):219-222.
  • Shivnaveen Bains and Asim A. Shah. "Review Article--Sexual Side Effects of Antipsychotic Drugs." Adv Pharmacoepidem Drug Safety. 2012 May 10;1:2.
  • Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CM, Iqbal S, Pillemer S, Perez AM, Foulkes A, Shah AA, Charney DS, Mathew SJ. "Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression Established in a Two-Site, Randomized, Controlled, Parallel-Arm Clinical Trial."
  • Shah AA. "Novel Approaches to Treatment Refractory Depression; An Overview." Psychiatric Annals. 2016;46(4):220-222.
  • Moukaddam N, Shah AA. "TRD an Overview." Psychiatric Annals. 2016;46(4):224-229.
  • Hashmi AM, Khawaja I, Shah AA. "Management of Treatment Resistant Depression in a young male: Complicated and challenging." Psychiatric Annals. 2016;46(4):216-219.
  • Tamez J, Du YB, Shah AA. "Management of Treatment Resistant Depression in Intensive Outpatient Programs." Psychiatric Annals. 2016;46(4):236-239.
  • Ostermeyer B, Flores A, Duke C, Shah AA. "Medical Decision-Making Capacity in Depression." Psychiatric Annals. 2016;46(4):247-252.
  • Shah AA. "Overview of Neurocognitive Disorders." Psychiatric Annals. 2016;46(2):89-91.
  • Shah AA, Aftab A. "Should physicians prescribe antipsychotics in dementia?." Psychiatric Annals. 2016;46(2):97-102.
  • Scott JG, Ostermeyer B, Shah AA. "Neuropsychological Assessment in Neuro-Cognitive Disorders." Psychiatric Annals. 2016;46(2):118-126.
  • Jones KC, Han JY, Shah AA. "The Cognitive Impairment Continuum: Areas of Controversy with use of Cognitive Enhancers." Psychiatric Annals. 2016;46(2):110-117.
  • Moukaddam N, Bejjani C, Shah AA. "Treatment Approaches to Neurocognitive Disorders." Psychiatric Annals. 2016;46(2):103-109.
  • Clionsky LN, Matorin A, David EH, Coverdale JH, Shah AA. "Medical Capacity and Competency in a Geriatric Population: Case Example Related to Self-Care and Placement." Psychiatric Annals. 2016;46(2):127-131.
  • Imran S. Khawaja IS, Jean-Noel F, Shah AA. "Polypharmacy as a cause of fall and worsening of RLS in an elderly woman." Psychiatric Annals. 2016;46(2):86-88.
  • Raythatha A, Shah A, Tucci V, Moukaddam N. "Synthetic Cannabinoids and Dysphonia: A Case Report." J Gen Practice. 2016;4:220.
  • Moukaddam N, Shah A. "From Dementia to Neurocognitive Disorders: DSM-5 Changes." New Directions in Psychiatry. 2015;35(4):263-278.
  • Hashmi A, Shah A. "Depression: An Overview and Diagnostic Changes in the DSM-5." New Directions in Psychiatry. 2015;35(4):247-260.
  • Shah A, Aftab A, Latorre S. "Psychiatric Disorders and Psychotropic Treatment in the Postpartum Period." New Directions in Psychiatry. 2015;35(3):229-245.
  • Wilson M, Nordstrom K, Shah A, Vilke GM. "Psychiatric Emergencies in Pregnant Women." Emerg Med Clin NAM. 2015;33(4):841–851.
  • Nathan SD, Hong M, Matorin A, Shah A. "Stabilization and Management of the Acutely Agitated or Psychotic Patient." Emerg Med Clin NAM. 2015;33(4):739–752.
  • Halmer T, Dark C, Beall R, Shah A. "Policy Considerations in Behavior Health Emergencies." Emerg Med Clin NAM. 2015;33(4):875–891.
  • Tran M, Kuo D, Matorin A, Shah A. "Depression and Suicidal Patient." Emerg Med Clin NAM. 2015;33(4):875–891.
  • Aftab A, Shah AA, Hashmi AM. "Pathophysiological Role of HERV-W in Schizophrenia." Journal of Neuropsychiatry and Clinical Neuro. 2016;28(1):17-25.
  • Shah AA, Banu S, McMorris R, Anandan S. "Intellectual Disability Disorder (IDD): from the DSM-IV-TR to the DSM-5.." New Directions in Psychiatry. 2016 October;36:193-206.
  • Tucci V, Moukaddam N, Patel N, Laufman L, Shah AA, Peacock WF. "Epic Fail! Poor Neuropsychiatric Documentation Practices in Emergency Psychiatric Patients." Emergency Medicine. 2016 July;6(4)
  • Moukaddam N, Tucci V, Galwankar S, Shah AA. "In the Blink of An Eye: Instant Countertransference and Its Application in Modern Healthcare." J Emerg Trauma Shock. 2016;9:95-96.
  • Jani S, Johnson RS, Banu S, Shah S. "Cross-Cultural Bias in the Diagnosis of Borderline Personality Disorder." Bull Menninger Clin. 2016;80(2):146-165.
  • Shah, A, Han J. "Anxiety Disorders:Subtypes, Diagnosis, Treatment and Neurological Comorbidities." CONTINUUM: Lifelong Learning in Neurology. 2015;21(3):772-782.
  • Lee S, Tucci V, Moukaddam N, Worley A, Shah AA. "Pregnant and abandoned: the multiple hurdles of medically clearing and admitting a pregnant patient to an inpatient psychiatric unit.." Journal of Psychiatry and Mental Health. 2016;1
  • Shah AA, Aftab A. "Are Psychotropic Drugs Safe to use During Lactation?." Psychiatric Annals. 2015 February;45(2):77-82.
  • Shah, A. "Women's Issue." Psychiatric Annals. 2015;45(2):68-69.
  • Shah A, Khawaja IS, Aftab A. "Are Psychotropics Drugs Safe to Use During Pregnancy?." Psychiatric Annals. 2015 February;45(2):71-76.
  • Tucci V, Liu J, Matorin A, Shah A, Moukaddam N. "Like the Eye of the Tiger: Exclusionary Criteria as Administrative Obstacles in the Medical Clearance Process." Emergency Psychiatry (in review). 2016
  • Tucci V, Moukaddam N, Matorin A, Shah A, Onigu-Otite E, Santillanes. "Eenie, meenie, miney, moe: Inpatient Psychiatric Facility Exclusionary Criteria and the Emergency Pediatric Psychiatric Patient." Int J Acad Med (submitted). 2016
  • Worley A, Moiz S, Moukaddam N, Tucci V, Shah A, Wilson M.. "Depression and Pregnancy." Medical J of Ob Gyn (submitted). 2016 June
  • Moukaddam N, Mathai D, Matorin A, Shah A. "Paradoxical Increase in Synthetic Cannabinoid Emergency-Related Presentations After City Wide Ban: Lessons From Houston, Texas." Bull Menninger Clin (accepted). 2016 August
  • Moukaddam N, Moiz S, Worley A, Shah A, Tucci V. "Teratogenic Potential of Commonly Prescribed Psychotropic Drugs." Med J Ob Gyn (in progress). 2016
  • Medford-Davis L, Moukaddam N, Laufman, Matorin A, Shah A, Tucci V. "True Costs of Medical Clearance: Accuracy and Disagreement Between Psychiatry and Emergency Medicine." Emergency Medicine J (submitted). 2016
  • 5. Matorin A, Shah Asim, Ruiz Pedro. "Clinical Manifestations of Psychiatric Disorders." Kaplan & Sadock's Comprehensive Textbook of Psychi. 2017

Memberships

American Psychiatric Association, 2000 - present
National Network of Depression Centers (NNDC)
American College of Psychiatrists

Funding

Esketamine
BCM IRB Protocol # H-37181
PI - A Randomized, Double Blind, Multicenter, active-controlled study of intra nasal plus an oral antidepressant for relapse prevention in Treatment resistant depression
OBSERVEMDD0001
H-35911
PI - A Prospective, Longitudinal, Observational Study to Evaluate Potential Predictors of Relapse in Subjects with Major Depressive Disorder Who Have Responded to Antidepressant Treatment
Does countertransference in providers affect medical decision making
H-35120
Co-PI - Screening and long- term 5 year naturalistic cohort study collecting clinical data on subjects with primary mood disorders
6. A new smart phone and online usage based evaluation for depression (SOLVD)
BCM IRB Protocol # H-36157
Co-PI
SBIRT Resident Teaching Grant
Faculty Champion
To educate and train internal medicine, family practice, psychiatry and pediatrics residents from internship to screen, evaluate and manage patients with substance use (SBIRT)
Corcept C-1073-14
BCM IRB Protocol # H-32760
PI, Study to Confirm a Diagnosis of Major Depressive Disorder with Psychotic Features and Screen Potential Patients. Phase 3 double blind study designed to assess the use of mifepristone and its effects on the HPA axis thus reducing psychotic symptoms in patients with Psychotic Depression.
BP-25712
Hoffman La-Roche Ltd.
PI - A multicenter, randomized, double blind, placebo controlled parallel group study to investigate the efficacy and safety of RO4005819 versus placebo, as adjunctive therapy in patients with major depressive disorder having inadequate response to ongoing antidepressant treatment
Efficacy and Tolerability of Riluzole in Treatment Resistant Depression
R01MH085054
CO-PI - The goal of this 4-site NIH collaborative R01 is to study the efficacy and safety of the glutamate modulator riluzole in patients with treatment-resistant depression and to investigate biomarkers predictive of response. BCM IRB Protocol # H-26581
CN-162-010
Bristol-Myers Squibb Company
PI - A multicenter, randomized, double-blind 58 week rollover study to assess the safety and tolerability of BMS-820836 in patients with treatment-resistant major depression. BCM IRB Protocol # H-29010
CN-162-007
Bristol-Myers Squibb Company
PI - Multi-center, randomized, double-blind, active-controlled, comparative, fixed-dose, dose-response study of the efficacy and safety of BMS-820836 in patients with treatment-resistant major depression. BCM IRB Protocol # H-28942
EVT 101/102
Evotec Neurosciences GmbH
PI - A 4-Week, Randomized, Double-blind, Parallel-Group Placebo-Controlled Study to Investigate the Safety and Efficacy of EVT 101 as Monotherapy in Patients With Treatment-Resistant Major Depression. This proof-of-concept 4-week placebo-controlled multicenter trial tests the safety and efficacy of an oral NR2B antagonist in patients with treatment-resistant depression. BCM IRB Protocol # H-26893
JNJ2648911MDD2001
Johnson & Johnson
PI - A Randomized, Double Blind, Parallel-Group, Active-and Placebo-Controlled Study to Assess the Efficacy and Safety of JNJ-26489112 in Adult Subjects with Major Depressive Disorder. BCM IRB Protocol # H-26841
Adjunctive IV Ketamine in Treatment-Resistant Depression
- #NARSAD Grant
The Brain and Behavior Research Fund
Co-PI - The goal of this randomized controlled trial is to test the safety, efficacy, and time-to-response of repeated dose intravenous Ketamine as adjunctive therapy to a SSRI for severely symptomatic patients with MDD. BCM IRB Protocol # H-26488
Optimization of IV Ketamine for Treatment Resistant Major Depression
NIMH - RO1MH081870-01A2
Co-PI - The goal of this study is to test the safety, tolerability, and acute efficacy of a single subanesthetic dose of intravenous Ketamine in patients with treatment-resistant major depressive disorder, using a randomized, triple-blind, midazolam-controlled, parallel-arm design. BCM IRB Protocol # H-26303

Professional Development

Efficaciousness of mental health outreach in religious settings
Sponsor: Association of Academic Psychiatry’s Annual Meeting
Gupta V, Shah AA, Singh H, Coverdale J, Harris T. (Poster Presentation) September 2010.
Bupropion Induced Bruxism
Sponsor: American Psychiatric Association’s Annual Meeting
Singh H, Shah AA, Gupta V, Wadha R. (Poster Presentation)
Efficaciousness of mental health outreach in religious settings
Sponsor: Association of Medicine and Psychiatry’s Annual Meeting
Gupta V, Shah AA, Singh H, Coverdale J, Harris T. Poster Presentation
Bupropion Induced Bruxism
Sponsor: Association of Medicine and Psychiatry’s Annual Meeting
Singh H, Shah AA, Gupta V, Wadha R. Poster Presentation
Risperidone Induced Hyperprolactinemia
Sponsor: Association of Medicine and Psychiatry’s Annual Meeting
Shah AA, Gupta V, Wadha R. Poster Presentation
Caffeine Induced QTc Prolongation
Sponsor: Association of Medicine and Psychiatry’s Annual Meeting
Shah AA, Gupta V, Wadha R. (Poster Presentation)
Risperidone Induced Hyperprolactinemia
Sponsor: Institute on Psychiatric services
Shah AA, Gupta V, Wadha R. (Poster Presentation)
Paliperidone Induced Hyperprolactinemia
Sponsor: Institute on Psychiatric services
Wadha R, Gupta V, Shah AA. Poster Presentation
Improvements in Citalopram Sexual Dysfunction by Switching to Escitalopram.
Sponsor: APA’s 165th Annual Meeting
Avellaneda AA, Lopez L, Shah AA. (Submission ID Number 34426)
Psychiatry Resident Training in Screening, Brief Intervention, and Referral to Treatment for Alcohol and Substance Use Disorders
Sponsor: 66th Annual APA meeting
Shah AA, Martin CD, Bray JH, Kowalchuk A, Waters V, Laufman L, Shilling EH, Lopez Y III, May 19, 2013.
Psychiatry Resident Training in Screening, Brief Intervention, and Referral to Treatment for Alcohol and Substance Use Disorders
Sponsor: 65th Institute of Psychiatric Services
Shah AA, Martin CD, Bray JH, Kowalchuk A, Waters V, Laufman L, Shilling EH, Lopez Y III, October 12, 2013.
Implementation of Scheduled Medication Policy in Psychiatric Emergency Center Admissions
Sponsor: 65th Institute on Psychiatric Services
Moukaddam N, Matorin A, Shah AA, October 10-13, 2013.
Development of a Standardized Medical Clearance Form for a Psychiatric Emergency Center
Sponsor: 65th Institute on Psychiatric Services
Moukaddam N, Shah AA, Matorin A, Horton C, October 10-13, 2013
Addressing systematic barriers in access to care for Bhutanese refugees in Houston: Experience from the Refugee Health & Leadership Academy
Sponsor: 167th Annual Meeting of American Psychiatric Association
Cai C, Banu S, Moukaddam N, Pilgrim P, Champlin M, Shah AA., May 3-7, 2014
Crossing Cultural Borders: A Resident Training Curriculum to Address the Needs of Refugees
Sponsor: Association of Academic Psychiatry
Asghar-Ali AA, Banu S, Jani S, Melton B, Shah AA. , September 17-20, 2014
Is it Ethical to use Valproate (Category D) in Women of child bearing Age?
Sponsor: 66th Institute on Psychiatric Services
Shah AA, Wadhwa R, Gupta V, Contreras VM. October 30-November 2, 2014
Integrating Licensed Chemical Dependency Counseling Services Into Psychiatric Emergency Center
Sponsor: 66th Institute on Psychiatric Services
Moukaddam N, Shah AA, Matorin A, Aoshima A. October 30-November 2, 2014
Addressing Systematic Barriers in access to care for Bhutanese refugees in Houston: Experience From the Refugee Health & Leadership Academy
Sponsor: 66th Institute on Psychiatric Services
Cecilia Cai, BS Sophia Banu MD, Nidal Moukaddam MD, Petra Pilgrim, MD Marie Champlin MD, Asim Shah MD, October 30-November 2, 2014. (encore poster)
What is New in Medical Clearance: Real-life Examples at the Confluence of Psychiatric and Emergency Care
Sponsor: 5th Annual National Update on Behavioral Emergencies
Moukaddam N, Tucci V, Matorin A, Shah AA. December 10-12, 2014
Culturally Competent Psychiatry for Refugees: A Pilot Program of a Standardized Mode
Sponsor: Annual Meeting Society for the Study of Psychiatry and Culture
Dinh, Jani SN, Banu S, Du Y, Shah AA. April 23-25, 2015.